While this finding is not suggestive of exquisite stabilization of EWSR1-NFATc2 fusion positive sarcomas to mTOR combination therapy, when linked with the other presented evidence a case could be made for mTOR as a potential therapeutic target in this disease. This evidence concerns the gene NFATC2 and sarcoma.